About us

Epiphany Biosciences' Mission is to develop new therapeutics and diagnostic technologies that treat or prevent the spread of diseases of viral origin. To support this mission, Epiphany has assembled a truly world-class team of virologists, clinicians, and drug development experts.

Epiphany is a privately-held company located in San Francisco. The company raised $36 million in a Series A financing in March 2007.

More about Valomaciclovir (EPB-348)

Valomaciclovir is a late-stage, next-generation novel herpes drug with broad-spectrum antiviral activity. Valomaciclovir has demonstrated potent activity and efficacy against the Varicella Zoster Virus (VZV) that causes shingles  and the Epstein-Barr Virus (EBV) that causes infectious mononucleosis.

Both a Phase 2b clinical study of Valomaciclovir for the treatment of shingles and a Phase 2 study of Valomaciclovir for the treatment of acute infectious mononucleosis have been successfully completed.

More about Shingles >>
More about Infectious Mononucleosis >>

Contact  |  Site Map

Copyright 2009-2012 Epiphany Biosciences, Inc.